Esperion reports Phase III data for hypercholesterolemia candidate

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) met the primary safety endpoint and key secondary efficacy endpoint in the Phase III CLEAR Harmony (1002-040) trial to treat high-risk atherosclerotic cardiovascular disease (ASCVD) patients with hypercholesterolemia, but also reported a higher incidence of fatal

Read the full 445 word article

User Sign In